Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
Metrics to compare | TYME | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTYMEPeersSector | |
---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |